Physician profile
Rachel Eliazbeth Cole
NPI 1104348358
$503,094.55
in general payments reported to CMS, 2019-2025
21 companies · $127K in 2025
The $127K reported for 2025 was more than what 99% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $43K · 2022: $81K · 2023: $137K · 2024: $116K · 2025: $127K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $333K · Travel and Lodging: $32K · Food and Beverage: $11K · Consulting Fee: $3,720 · Education: $93.26.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $332,780.00 |
| Travel and Lodging | $32,184.83 |
| Food and Beverage | $10,613.01 |
| Consulting Fee | $3,720.00 |
| Education | $93.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $475,527.70 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $21,381.74 | 2021-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $1,219.19 | 2021-2025 | Invega Sustenna, Invega Trinza, Spravato |
| Allergan, INC. | $825.00 | 2021 | |
| Alkermes, INC. | $489.80 | 2021-2025 | Aristada, Lybalvi |
| Teva Pharmaceuticals USA, INC. | $473.48 | 2022-2025 | Austedo Xr, Uzedy, Austedo |
| Ironshore Pharmaceuticals INC. | $470.97 | 2022-2024 | Jornay Pm |
| E.R. Squibb & Sons, L.L.C. | $455.07 | 2024-2025 | Cobenfy |
| Otsuka America Pharmaceutical, INC. | $418.21 | 2021-2025 | Abilify Maintena, Rexulti, Abilify Asimtufii |
| Lundbeck LLC | $334.25 | 2021-2024 | Abilify Asimtufii, Abilify Maintena |
| Vanda Pharmaceuticals INC. | $329.93 | 2021-2025 | Fanapt, Hetlioz |
| Neurocrine Biosciences, INC. | $329.07 | 2021-2025 | Ingrezza |
| Sunovion Pharmaceuticals INC. | $220.51 | 2021-2022 | |
| Corium, LLC | $178.44 | 2022-2023 | Azstarys |
| Axsome Therapeutics, INC. | $132.22 | 2023 | Auvelity |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $129.96 | 2021-2023 | Qelbree |
| Takeda Pharmaceuticals U.S.A., INC. | $69.63 | 2021-2022 | |
| Collegium Pharmaceutical, INC. | $46.78 | 2025 | Jornay Pm |
| Janssen Biotech, INC. | $24.42 | 2023 | |
| Almatica Pharma LLC | $21.45 | 2024 | Loreev Xr |
| Indivior INC. | $16.73 | 2023 | Perseris |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rachel Cole listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.